【摘要】 神经肿瘤反应评价（response assessment in neuro-oncology,RANO）标准在临床试验和实践中被广泛使用。但在使用过程中，不同的评估标准[高级别胶质瘤（high grade glioma,HGG）神经肿瘤评估标准（RANO-HGG）、改良RANO(modified RANO,m RANO)和免疫治疗RANO(immunotherapy RANO,i RANO)]常导致临床疗效评估的差异，也增加了究竟使用哪一套标准进行评估的不确定性。2023年9月RANO工作组针对所有神经胶质瘤制定了统一的新版神经肿瘤反应评估标准（RANO 2.0）。磁共振成像是神经肿瘤治疗反应评估的主要检查手段，而随着神经肿瘤治疗方式的多样化，神经肿瘤治疗反应的影像学表现也更加复杂。本文主要针对RANO 2.0的影像学部分进行介绍，目的是解析新版RANO中关于磁共振成像评价的技术和诊断要点，旨在为影像医学在成人神经胶质瘤治疗反应评价中的合理应用提供帮助。更多还原

【Abstract】 The response assessment in neuro-oncology(RANO) criteria are widely used in clinical trials and practice. However, in the process of using RANO standards, various criteria of RANO-high grade glioma(RANO-HGG), modified RANO(m RANO) and immunotherapy RANO(i RANO) lead to differences in the response assessment, and also increase the uncertainty of which set of criteria to be used for the clinical assessment. In September 2023, the RANO working group developed a new version of the update to the response assessment in neuro-oncology criteria for all gliomas in adults(RANO 2.0), in which, magnetic resonance imaging(MRI) is the main examination method for the assessment of treatment response of neuro-oncology, and with the diversification of neuro-oncology treatment methods, the imaging manifestations of neuro-oncology treatment response are becoming more complex than before. This article introduced the core imaging contents with the detailed illustration of the technical and diagnostic key points in the MRI evaluation in the RANO 2.0, and aimed to provide help for the rational application of imaging medicine in the assessment of treatment response of adult gliomas.更多还原